CHRS Coherus BioSciences
- 1.400
- +0.020+1.45%
- 1.420
- +0.020+1.43%
Coherus BioSciences News
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird
Coherus BioSciences Is Maintained at Outperform by Baird
Coherus BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Truist Financial Initiates Coherus BioSciences(CHRS.US) With Buy Rating
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus Biosciences (CHRS) Receives a Buy From Barclays
Coherus BioSciences Is Maintained at Outperform by Baird
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Cuts Target Price to $4
TD Cowen Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Coherus Biosciences: Strong Financial Performance and Strategic Cost Management Drive Buy Rating
Coherus BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
JonesTrading Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $8
Coherus BioSciences Analyst Ratings
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
No Data